Neteera raises an additional $6.7M Series B Extension

Neteera Technologies Ltd., an Israeli-based startup disrupting the contactless patient monitoring market, today announced the successful closing of a ~$6,7M Series B extension. The round was led by Aescuvest, a renowned healthcare investment firm, alongside Foxconn Technology Co., Ltd. (FTC), an associate of Hon Hai Precision Industry Co., Ltd., the largest electronics manufacturer globally.

The funds of this extension round will be used to expedite production, meet the increasing demand for Neteera’s platform, and to recruit more installation and deployment personnel. This significant step will allow Neteera to further solidify its leadership in the contactless patient monitoring market.

Partnering with Foxconn Technology Group, the world’s leading company and powerhouse in the electronics manufacturing market, will further boost Neteera’s international growth. A cooperation to produce Neteera’s products is already under way, with further business and technology collaborations in the pipeline.

“Neteera is an excellent medical equipment development company. We are delighted to participate in Neteera’s current round of funding and to become their manufacturing partner, providing strong support for the mass production of their products,” said William Hung, Chief Investment Officer at FTC.

In the face of challenging market conditions and VC funding slowdowns, Neteera has not only persevered but thrived. The startup’s big pull is its proven product-market-fit for a globally applicable problem, coupled with essential regulatory approvals, such as the FDA stamp.

Neteera successfully tackles a problem that we are all prone to. Our ageing populations deserve professional, humane care. Technological solutions such as Neteera’s platform are a suitable answer to combat the problems of our healthcare systems,” said Sebastian Gührs, Partner & Head of Investment at Aescuvest.

Founded in 2015, Neteera quickly gained recognition for its FDA-cleared remote patient monitoring platform, designed to enable continuous monitoring of patients’ biomarkers without the need for contact or patient involvement. The platform is improving patient care and operator efficiencies all over the globe.

Outside of raising money, Neteera has been working on expanding access to its contactless patient monitoring platform. In 2023, the company began selling its solution to a large number of long-term care facilities in the US and has a significant pipeline of ordered products that are currently being deployed.

We are proud to partner with such a renowned company as Foxconn to further expand our offering,” said Isaac Litman, CEO of Neteera. “This funding and cooperation will expedite our solution production and deployment, opening doors and allowing us to get one step closer to achieving our mission: saving life, improving patient care while reducing the burden on clinical staff.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.